Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia

• Status: Terminated
• Trial end date: 2020-03-29
• Target enrollment: 0
• Participant gender: All

Summary

2019 new coronavirus (2019-nCoV) infected pneumonia, namely severe acute respiratory infection (SARI) has caused global concern and emergency. There is a lack of effective targeted antiviral drugs, and symptomatic supportive treatment is still the current main treatment for SARI.

Vitamin C is significant to human body and plays a role in reducing inflammatory response and preventing common cold. In addtion, a few studies have shown that vitamin C deficiency is related to the increased risk and severity of influenza infections.

We hypothize that Vitamin C infusion can help improve the prognosis of patients with SARI. Therefore, it is necessary to study the clinical efficacy and safety of vitamin C for the clinical management of SARI through randomized controlled trials during the current epidemic of SARI.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ZhiYong Peng
• Treatments: Ascorbic Acid; Vitamins

Criteria

Inclusion Criteria:

1. ≥ 18 years old;

2. Diagnosed as serious or critical SARI (according to the 4th version of Diagnosis and Clinical management of 2019-nCoV infected pneumonia);

3. Being treated in the ICU.

Exclusion Criteria:

1. Allergic to vitamin C;

2. Dyspnea due to cardiogenic pulmonary edema;

3. Pregnant or breastfeeding;

4. Expected life is less than 24 hours;

5. There is a state of tracheotomy or home oxygen therapy in the past;

6. Previously complicated with end-stage lung disease, end-stage malignancy, glucose-6-phosphate dehydrogenase deficiency, diabetic ketoacidosis, and active kidney stone disease;

7. The patient participates in another clinical trial at the same time.